clinical trial · NCT05746559
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
Alexion Pharmaceuticals, Inc.·phase3·completed·n = 544
Chronic Kidney DiseaseCKDCardiac DiseaseCardiopulmonary BypassPlaceboRavulizumab
brief summary
The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent cardiac surgery with CPB.
started
Apr 6, 2023
primary completion
Oct 7, 2025
completion
May 7, 2026
last updated
Jun 30, 2026
official title
ARTEMIS: RAvulizumab to PRotect PaTients With Chronic Kidney DisEase (CKD) froM Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) and Subsequent Major Adverse Kidney Events (MAKE): A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol